leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...1415161718192021222324...235236»
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie, navitoclax (ABT 263) / AbbVie
    Enrollment closed:  Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax (clinicaltrials.gov) -  May 9, 2024   
    P1/2,  N=98, Active, not recruiting, 
    Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Recruiting --> Active, not recruiting
  • ||||||||||  Induction chemotherapy followed by CCRT or RT for patients with esophageal cancer (Lomond Auditorium) -  May 8, 2024 - Abstract #ESTRO2024ESRTO_60;    
    Preliminary results of our IndCT followed by CCRT/RT are feasible for esophageal cancer with encouraging preliminary outcome. This novel protocol deserves to study in future trials to compare with the standard neoadjuvant CCRT followed by surgery.
  • ||||||||||  Xtandi (enzalutamide capsule) / Pfizer, Astellas, Ibrance (palbociclib) / Pfizer
    ARREST  (Lomond Auditorium) -  May 8, 2024 - Abstract #ESTRO2024ESRTO_44;    
    P1
    The ARREST study demonstrated that SABR treatment to all sites of polymetastatic disease is feasible in selected patients. Doses up to 30 Gy in 5 fractions were delivered with minimal acute toxicity noted.
  • ||||||||||  Organ preservation in rectal cancer: the GRECCAR12 randomized phase 3 trial (NCT02514278) (Lomond Auditorium) -  May 8, 2024 - Abstract #ESTRO2024ESRTO_21;    
    P3
    Material/ In this randomized phase 3 trial, 218 patients with cT2T3 N0-1 M0 rectal cancer (tumor size ?4cm and ?10cm from the anal verge) received induction chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 every 2 weeks for 4 cycles), and chemoradiotherapy (50 Gy and concomitant capecitabine), or chemoradiotherapy. ICT with FOLFIRINOX increased 1-year organ preservation up to 71.7% in a selective approach for rectal cancer at the cost of increased but manageable toxicity.
  • ||||||||||  Avastin (bevacizumab) / Roche
    SBRT in colorectal cancer patients with 1-10 metastases: a multicenter pilot study (NCT05375708) (Lomond Auditorium) -  May 8, 2024 - Abstract #ESTRO2024ESRTO_15;    
    P2
    The initial treatment effect of SBRT in combination with systemic therapy seems promising in patients with mCRC. However, because of highly effective systemic therapy, 38% of lesions vanished during systemic treatment resulting in no patient with six or more radiated lesions.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date:  ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov) -  May 8, 2024   
    P3,  N=438, Active, not recruiting, 
    However, because of highly effective systemic therapy, 38% of lesions vanished during systemic treatment resulting in no patient with six or more radiated lesions. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Apr 2023 --> May 2024
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Diagnostic performance of Ga68-FAPI in signet ring cell carcinoma stomach in comparison to FDG: An initial experience (Exhibit Hall D - Science Pavilion (Convention Center); Screen 8; In-Person Only) -  May 8, 2024 - Abstract #SNMMI2024SNMMI_1352;    
    Our initial experience showed a promising impact of FAPI PET-CT in tailoring the diagnostic laparoscopy and management of SRCa patients. Figure 1: F18-FDG and Ga68-FAPI PET-CT MIP (image A and B), fused axial (image C, D, E, F and G) and CECT axial image (image H).
  • ||||||||||  Opdivo (nivolumab) / BMS
    Enrollment closed, Trial completion date, Trial primary completion date:  Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) -  May 7, 2024   
    P1,  N=28, Active, not recruiting, 
    Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025 Recruiting --> Active, not recruiting | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Apr 2025
  • ||||||||||  hydroxocobalamin (vit B12) / Generic mfg.
    Journal:  The MMACHC variant c.158T>C: Mild clinical and biochemical phenotypes and marked hydroxocobalamin response in cblC patients. (Pubmed Central) -  May 6, 2024   
    In cblC, deficient activation of cobalamin results in methylcobalamin and adenosylcobalamin deficiency, elevating methylmalonic acid (MMA) and total plasma homocysteine (tHcy)...In contrast, c.271dupA homozygotes showed marked psychomotor retardation, retinopathy and feeding problems despite penta-therapy (hydroxocobalamin, betaine, folinic acid, l-carnitine and acetylsalicylic acid)...Also, the distribution pattern of cobalamin species was qualitatively different between cells from compounds and from homozygotes. Compared to the classic cblC phenotype presented by c.271dupA homozygous patients, c.[158T>C];[271dupA] compounds had mild clinical and biochemical phenotypes and responded strikingly to hydroxocobalamin monotherapy.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Biomarker, Journal, Tumor microenvironment:  Use of deep learning to evaluate tumor microenvironmental features for prediction of colon cancer recurrence. (Pubmed Central) -  May 6, 2024   
    Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphological differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Journal:  Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases (Pubmed Central) -  Apr 30, 2024   
    Results A total of 198 patients with potentially resectable colorectal cancer with simultaneous multiple liver metastases were included in this study.Sixty-six patients were cured by neoadjuvant chemotherapy(FOLFOX or FOLFIRI),including 30 patients in the surgical resection group and 36 patients in the microwave ablation group(with 57 tumors ablated).After the first ablation,54(94.74%)tumors achieved complete ablation,and all of them reached no evidence of disease status after re-ablation.The microwave ablation group had shorter operation duration,less intraoperative blood loss,shorter time to first postoperative anal exhaust,shorter time of taking a liquid diet,shorter hospital stay,and lower hospitalization cost than the surgical resection group(all P<0.001).In addition,the microwave ablation group had lower visual analogue scale score(P<0.001)than the surgical resection group.The incidences of complications such as incision infection(P=0.740),anastomotic fistula(P=1.000),and anastomotic stenosis(P=1.000),the overall survival period(P=0.191),and the disease-free survival period(P=0.934)showed no significant differences between the two groups. Conclusions For patients with colorectal cancer with simultaneous multiple liver metastases initially assessed as potentially resectable,laparoscopic primary resection+surgical resection/microwave ablation after conversion therapy was safe,effective,and had similar survival outcomes.Microwave ablation outperformed surgical resection in postoperative recovery,economy,and tolerability,being worthy of clinical promotion.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal:  Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma. (Pubmed Central) -  Apr 30, 2024   
    Conclusions For patients with colorectal cancer with simultaneous multiple liver metastases initially assessed as potentially resectable,laparoscopic primary resection+surgical resection/microwave ablation after conversion therapy was safe,effective,and had similar survival outcomes.Microwave ablation outperformed surgical resection in postoperative recovery,economy,and tolerability,being worthy of clinical promotion. The combination of HAIC-FOLFOX with lenvatinib and PD-1 inhibitors as a first-line therapy has exhibited notable therapeutic efficacy and well-tolerated adverse events among patients with high-burden HCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
    Journal:  Evaluation of Stages, Treatment Protocols, and Outcomes of Colorectal Cancer among West Bank Patients. (Pubmed Central) -  Apr 27, 2024   
    More studies need to be undertaken to investigate the actual application of chemotherapy protocols, and survival would benefit from the involvement of clinical pharmacists in the chemotherapy protocol selection, dosing, frequency, and follow-up. The present study advocates for greater public awareness of CRC and attests to the merits of screening by primary care professionals, which can help to avoid this serious illness and to promote a better prognosis.
  • ||||||||||  Avastin (bevacizumab) / Roche
    P2 data, Journal, Metastases:  First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). (Pubmed Central) -  Apr 27, 2024   
    Unlike bevacizumab, the addition of aflibercept, an antibody acting as an anti-angiogenic agent, has never been evaluated in this context...This multicenter phase II non-comparative trial evaluated the addition of aflibercept to infusional 5-fluorouracil/folinic acid (LV5FU2 regimen) as first-line treatment in patients unfit to receive doublet cytotoxic chemotherapy...Given the 6-month PFS, the study can be considered positive. However, the toxicity of aflibercept in this population was high, and continuation of the trial into phase III is not envisaged.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
    Review, Journal, HEOR, Metastases:  Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review. (Pubmed Central) -  Apr 26, 2024   
    However, the toxicity of aflibercept in this population was high, and continuation of the trial into phase III is not envisaged. From an initial pool of 1345 articles, 11 relevant studies were selected for inclusion, encompassing a diverse range of systemic treatments, including panitumumab combined with FOLFOX4 and FOLFIRI, irinotecan paired with panitumumab, regorafenib followed by cetuximab
  • ||||||||||  ASP3082 / Astellas
    Enrollment change:  3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 26, 2024   
    P1,  N=541, Recruiting, 
    The study demonstrated an encouraging efficacy and manageable safety profile of neoadjuvant sintilimab plus FLOT in HER2-negative locally advanced G/GEJ cancer, which suggested a potential therapeutic option for this population. N=356 --> 541
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_6902;    
    Since the and PRODIGE and MPACT trials, FFX, GnP, or gemcitabine monotherapy have been the primary recommended 1L treatments for most pts with mPDAC. While recent years have seen an increase in the availability of targeted and CPI therapies appropriate for small subgroups of mPDAC pts, in a RW sample, almost all pts received one of the three standard therapies.